Table 1.
Patient Sociodemographic and Clinical Characteristics (n = 92)*
| Characteristic | Total Patients |
|
|---|---|---|
| No. | % | |
| Anastrozole level, ng/mL | ||
| 0.0 | 2 | 2.2 |
| 1.0-99.0 | 14 | 15.2 |
| 100.0-199.0 | 38 | 41.3 |
| 200.0-299.0 | 23 | 25.0 |
| 300.0-399.0 | 8 | 8.7 |
| 400.0-499.0 | 3 | 3.3 |
| 500.0-599.0 | 2 | 2.2 |
| 600.0-699.0 | 2 | 2.2 |
| No. of years taking anastrozole | ||
| ≤ 1 | 35 | 38.0 |
| 2 | 15 | 16.3 |
| 3 | 17 | 18.5 |
| 4 | 13 | 14.1 |
| 5 | 11 | 12.0 |
| > 5 | 1 | 1.1 |
| No. of days since last pill taken | ||
| 0 | 58 | 63.7 |
| 1 | 31 | 34.1 |
| > 1 | 2 | 2.2 |
| Age, years | ||
| 41-50 | 9 | 9.8 |
| 51-60 | 30 | 32.6 |
| 61-70 | 34 | 36.9 |
| 71-80 | 9 | 9.8 |
| 81-90 | 9 | 9.8 |
| Unknown | 1 | 1.1 |
| Race | ||
| African American/black | 17 | 18.5 |
| Asian/Pacific Islander | 1 | 1.1 |
| Hispanic | 17 | 18.5 |
| White | 52 | 56.5 |
| Other | 5 | 5.4 |
| Birthplace | ||
| United States | 53 | 57.6 |
| Non–United States | 39 | 42.4 |
| Educational attainment | ||
| ≤ Grade school | 12 | 13.2 |
| High school | 25 | 27.5 |
| College | 28 | 30.8 |
| Graduate school | 26 | 28.6 |
| Employment status | ||
| Employed | 37 | 40.2 |
| Not employed | 55 | 59.8 |
| Annual household income | ||
| ≤ $15,000 | 16 | 17.4 |
| $15,001 to $30,000 | 12 | 13.0 |
| $30,001 to $50,000 | 9 | 9.8 |
| $50,001 to $70,000 | 8 | 8.7 |
| > $70,000 | 22 | 23.9 |
| Medical health insurance | 92 | 100.0 |
| Prescription drug coverage | 89 | 96.7 |
| Disease stage† | ||
| I | 50 | 54.3 |
| II | 25 | 27.2 |
| III | 7 | 7.6 |
| Unknown | 10 | 10.9 |
| Breast cancer treatment† | ||
| Surgery‡ | ||
| Mastectomy | 35 | 38.0 |
| Lumpectomy | 62 | 67.4 |
| Adjuvant treatment‡ | ||
| Chemotherapy | 46 | 50.0 |
| Radiation therapy | 54 | 58.7 |
*
For postmenopausal women with hormone-sensitive breast cancer for whom anatrozole was prescribed between August 2010 and March 2011.
†
Self-reported.
‡
Categories were not mutually exclusive; total is greater than 100%.